Anzupgo (Delgocitinib)

Delgocitinib is a medicine used to treat long-lasting eczema on the hands. It is a cream that you rub onto the skin of your hands. It works by calming the parts of the immune system that cause itching, redness and swelling.

Brand names:Anzupgo
Medication

What people taking Anzupgo (Delgocitinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Anzupgo (Delgocitinib) for Eczema?

NameHow it went

About Anzupgo (Delgocitinib)

What It's For

Delgocitinib, sold as Anzupgo, is a prescription cream for adults with moderate to severe chronic hand eczema: inflamed, itchy, often cracked and painful skin on the hands and wrists that lasts for months or keeps returning. Hand eczema can come from irritants such as frequent washing or work chemicals, from an allergy to something the skin touches, or from a tendency to eczema in general, and many people have more than one cause at once. Anzupgo is meant for people whose hand eczema has not improved enough with corticosteroid (steroid) creams or ointments, or who should not keep using them. It does not replace the basics of hand care, such as regular moisturizing, protective gloves and avoiding known triggers. It is approved for adults only; its safety and effectiveness have not been established in children or teenagers.

How It Works

Eczema flares are driven by immune signaling in the skin. Immune cells release messenger proteins called cytokines, and many of these pass their signal into skin and immune cells through a family of enzymes called Janus kinases (JAKs). That signal switches on genes that produce inflammation, itch and the skin damage seen in eczema. Delgocitinib is a JAK inhibitor. It blocks all four members of the JAK family, which dampens this inflammatory signaling in the skin where the cream is applied. Researchers have not fully worked out exactly how this translates into improvement in hand eczema, and only a small amount of the medicine reaches the bloodstream when it is used as directed.

Dosage & Administration

Anzupgo is a 2% cream, supplied in 30-gram tubes. It is applied as a thin layer twice a day to the affected skin of the hands and wrists only, after cleaning and drying the area. It is not for use on other parts of the body, and it should be kept away from the eyes, mouth and inside the vagina; rinse with water if it gets on these areas. There is a limit on how much to use: no more than 30 grams (one tube) every two weeks, or 60 grams a month. Before starting, the prescriber may check that vaccinations are up to date, including the shingles vaccine.

Side Effects

In the main clinical trials, side effects were about as common with Anzupgo as with the plain cream base it was compared against. The most noticeable ones, each reported in about 1 in 100 people or fewer, were pain, tingling, itching or redness where the cream was applied, and bacterial infections of the skin, such as infection around a fingernail or of a finger. Blood tests occasionally showed low white blood cell counts. Because the medicine calms part of the immune response, infections deserve attention. A few people in the trials developed shingles, and one developed eczema herpeticum, a spreading herpes virus infection of eczema skin that causes clusters of painful blisters or sores. Contact the prescriber promptly about any sign of infection, such as fever, a painful blistering rash, or skin on the hands that becomes hot, swollen and increasingly painful.

Interactions & Warnings

Anzupgo should not be used during an active or serious infection, and it may be paused if a serious infection or shingles develops. People with recurring infections, past tuberculosis exposure or a condition that weakens the immune system should talk through the trade-offs first. It is not recommended for people with active hepatitis B or C, and some prescribers screen for these before starting. Live vaccines should be avoided just before, during and right after treatment. Non-melanoma skin cancers, such as basal cell carcinoma, have been reported in people using the cream. Periodic skin checks of the hands are recommended, especially for people with a history of skin cancer or heavy sun exposure, and it helps to limit sun on treated skin and avoid sunlamps. Anzupgo is not recommended alongside other JAK inhibitors, such as JAK inhibitor pills used for eczema or arthritis, or with strong immune-suppressing medicines. JAK inhibitor pills carry serious warnings about heart problems, blood clots and cancer; it is not known whether this cream, which reaches the bloodstream only in small amounts, shares those risks. There is not enough information on use during pregnancy. During breastfeeding, avoid touching the nipple area right after applying the cream so the baby does not swallow it.

What to Expect

Improvement is gradual. In two 16-week trials, about half of people using Anzupgo had a substantial drop in itch and pain, compared with about a quarter of those using the plain cream base. Fully clear or almost clear hands were less common: about 20 to 29 percent of people reached that point, compared with 7 to 10 percent on the plain cream. Many people improve partly rather than completely, so it helps to agree with the prescriber on what counts as success and when to reassess. Chronic hand eczema tends to flare and settle. In an extension study, people restarted the cream when their eczema returned and stopped when it cleared, and the share of people with well-controlled hands held steady for up to a year of total treatment. Long-term use beyond that is still being studied. Throughout treatment, the basics still matter: moisturizing often, wearing gloves for wet work or chemicals, and identifying any allergen through patch testing if an allergy is suspected.

Questions to Ask Your Doctor

  1. 1.What is likely causing my hand eczema, and would patch testing help find an allergy?
  2. 2.Why is Anzupgo a better fit for me than continuing steroid creams or trying another treatment?
  3. 3.How long should I use it before we decide whether it is working, and can I use it only during flares?
  4. 4.Are my vaccines, including the shingles vaccine, up to date before I start?
  5. 5.How often should my hands be checked for skin changes, and what infection signs should make me call you?

Last reviewed • Oct 2026

Educational content, not medical advice.